MBX Biosciences results, highlights

 Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025

MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2H 2025

Investigational New Drug submission anticipated in Q2 2025 for MBX 4291 in obesity

$262.1 million in cash, cash equivalents and marketable securities as of December 31, 2024; expected to support operations into mid-2027

https://www.globenewswire.com/news-release/2025/03/17/3043631/0/en/MBX-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html